Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240424 | 0.77 | LMNA (0.63) | KDM4ECYP3A4LMNACYP2D6CYP1A2 | |
| SCHEMBL7948611 | 0.76 | KDM4E (0.61) | KDM4ECYP3A4LMNACYP2D6CYP1A2 | |
| SCHEMBL276518 | 0.74 | KDM4E (1.00) | KDM4ECYP3A4LMNACYP2D6CYP1A2 | |
| SCHEMBL4368137 | 0.74 | KDM4E (0.59) | KDM4ECYP3A4LMNACYP2D6CYP1A2 | |
| SCHEMBL30020533 | 0.74 | KDM4E (0.59) | KDM4ECYP3A4LMNACYP2D6CYP1A2 | |
| SCHEMBL3147494 | 0.74 | KDM4E (0.59) | KDM4ECYP3A4LMNACYP2D6CYP1A2 | |
| SCHEMBL4207818 | 0.74 | KDM4E (0.59) | KDM4ECYP3A4LMNACYP2D6CYP1A2 | |
| SCHEMBL276517 | 0.74 | CYP3A4 (0.59) | KDM4ECYP3A4LMNACYP2D6CYP1A2 | |
| SCHEMBL12271 | 0.74 | KDM4E (0.59) | KDM4ECYP3A4LMNACYP2D6CYP1A2 | |
| SCHEMBL3805113 | 0.74 | CYP1A2 (0.59) | KDM4ECYP3A4LMNACYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1414457-B1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1320367-A4 | PROCESS FOR THE PREPARATION OF DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1699450-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | Darpharma, INC. (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7091212-B2 | Chiral dinapsoline | PURDUE RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| WO-2006012640-A2 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005062894-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | DARPHARMA, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1414457-A4 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1414457-A1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040063741-A1 | Chiral dinapsoline | SIT SING-YUEN (US) | 2004-04-01 | — | — | US | disclosed |
| US-6645975-B1 | Reducing, deprotecting and optionally alkylating chemical intermediates to form 8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-naphtho(1,2,3-de)isoquinoline, used as dopamine receptor agonists | PURDUE RESEARCH FOUNDATION | 2003-11-11 | — | — | US | disclosed |
| EP-1320367-A1 | PROCESS FOR THE PREPARATION OF DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2003013532-A1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002013827-A1 | PROCESS FOR THE PREPARATION OF DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | KDM4E 4742/4885CYP3A4 1157/4885LMNA 4480/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | KDM4E 4653/4885CYP3A4 590/4885LMNA 4167/4885 |
| US-20040063741-A1 | Chiral dinapsoline | NAP1L1, DDAH1, NAP1L4 | KDM4E 3583/4885CYP3A4 388/4885LMNA 3867/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | KDM4E 4741/4885CYP3A4 1121/4885LMNA 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.